Liver subcellular fractions from rats treated by organosulfur compounds from Allium modulate mutagen activation.
The effects of in vivo administration of naturally occurring organosulfur compounds (OSCs) from Allium species were studied on the activation of several mutagens. Male SPF Wistar rats were given p.o. one of either diallyl sulfide (DAS), diallyl disulfide (DADS), dipropyl sulfide (DPS) or dipropyl disulfide (DPDS) during 4 consecutive days and the ability of hepatic S9 and microsomes from treated rats to activate benzo[a]pyrene (BaP), cyclophosphamide (CP), dimethylnitrosamine (DMN), N-nitrosopiperidine (N-PiP) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was determined in the Ames test. Administration of DAS, DPS and DPDS resulted in a significant increase of the activation of BaP, CP, N-PiP and PhIP mediated by S9 and microsomes while DADS treatment only increased the mutagenicity of PhIP. In contrast, S9 from DADS-treated rats significantly inhibited the mutagenicity of N-PiP and BaP. DAS, DADS and DPS strongly inhibited DMN mutagenicity while DPDS enhanced it. To understand the mechanisms underlying these effects, the modifications of the activities of specific isozymes of CYP involved in the activation of these mutagens were studied. DAS, DPS and DPDS strongly enhanced pentoxyresorufin O-dealkylase (PROD) activity related to CYP2B and slightly increased ethoxyresorufin O-deethylase (EROD) and methoxyresorufin O-demethylase (MROD) activities related to CYP1A family. DADS exerted the same effects than other OSCs but to a lesser extent. p-Nitrophenol hydroxylase (PNPH) activity related to CYP2E1 was inhibited by DAS and DADS, whereas DPDS significantly increased this activity. Hence, the effects of OSCs on the mutagenicity of several genotoxic compounds are mediated by modification (enhancement or inhibition) of specific CYP involved in their activation.
Guyonnet
D
D
Institut National de la Recherche Agronomique, Unité de Toxicologie Nutritionnelle, BV 1540, 17 rue Sully, 21034, Dijon, France.
Belloir
C
C
Suschetet
M
M
Siess
M H
MH
Le Bon
A M
AM
D000490:Allium / Q000737:chemistry*; D000498:Allyl Compounds / Q000494:pharmacology; D000818:Animals; D001564:Benzo(a)pyrene / Q000633:toxicity; D003520:Cyclophosphamide / Q000633:toxicity; D019363:Cytochrome P-450 CYP1A1 / Q000187:drug effects / Q000378:metabolism; D019362:Cytochrome P-450 CYP2B1 / Q000187:drug effects / Q000378:metabolism; D019392:Cytochrome P-450 CYP2E1 / Q000187:drug effects / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D004128:Dimethylnitrosamine / Q000633:toxicity; D004220:Disulfides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000633:toxicity; D008110:Liver Extracts / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D009602:Nitrosamines / Q000633:toxicity; D010088:Oxidoreductases / Q000187:drug effects / Q000378:metabolism; D011407:Propane / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013347:Subcellular Fractions / Q000187:drug effects / Q000201:enzymology; D013440:Sulfides / Q000494:pharmacology*
D000498:Allyl Compounds; D004220:Disulfides; D007093:Imidazoles; D008110:Liver Extracts; D009153:Mutagens; D009602:Nitrosamines; D013440:Sulfides; D001564:Benzo(a)pyrene; C028009:diallyl disulfide; C038491:allyl sulfide; C002743:N-nitrosopiperidine; D003520:Cyclophosphamide; D003577:Cytochrome P-450 Enzyme System; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; D010088:Oxidoreductases; C076307:methoxyresorufin-O-demethylase; D019392:Cytochrome P-450 CYP2E1; D019363:Cytochrome P-450 CYP1A1; D019362:Cytochrome P-450 CYP2B1; D004128:Dimethylnitrosamine; C087894:dipropyl sulfide; D011407:Propane